Maveropepimut-S, pembrolizumab and low dose cyclophosphamide in metastatic ovarian cancer: phase 1/2 PESCO trial
Amit M. Oza
Nature Communications, Published online: 14 May 2026; doi:10.1038/s41467-026-72125-0 Epithelial ovarian cancer (EOC) frequently relapses with rising chemoresistance. This phase 1/2 trial evaluates MVP-S vaccination plus pembrolizumab and cyclophosphamide in recurrent EOC, assessing safety, clinical efficacy outcomes, and MVP-S-specific immunity.